Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7L1P5 refers to a pseudogene related to the ribosomal protein L7-like 1 (RPL7L1)[3]. Pseudogenes are non-coding genomic sequences that are similar to known genes but are typically non-functional due to mutations, truncations, or lack of regulatory elements. The canonical RPL7L1 (Ribosomal protein L7-like 1) is a protein-coding gene involved in RNA binding and is associated with cellular processes including ribosome biogenesis and maturation of large subunit rRNA[3]. However, RPL7L1P5 itself does not encode a functional protein, nor is it recognized as a therapeutic target, biomarker, or mechanistic entity in disease or pharmacology[3]. There are no known biological functions, disease roles, associated drugs, or safety concerns for RPL7L1P5. Its classification is other/pseudogene. If the intent was Ribosomal protein L7-like 1 (RPL7L1) rather than the pseudogene, that would correspond to a legitimate protein-coding gene associated with cancer biology, immune suppression, and therapeutic biomarkers[1][3]. RPL7L1P5 is not the same as RPL7L1, and no structured information about targeting, function, or disease relevance exists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7-like 1 pseudogene 5 (RPL7L1P5).